Block & Leviton Reminds Ocular Therapeutix, Inc. (OCUL) Shareholders Of Important Deadline In Securities Fraud Class Action And Encourages Them To Contact The Firm

BOSTON, July 25, 2017

On Jul 6, 2017, near the close of trading, the investor website Seeking Alpha published an article entitled "Ocular: A Poke In The Eye," reporting that Ocular is on "the brink of collapse" and that they may be "misleading investors" about ongoing manufacturing issues and the Company's communications with the FDA about those issues.

On this news, Ocular's stock fell more than 30% to close at $7.12 on July 7, 2017, and has continued to slide below $6.50 per share, causing tens of millions in losses to shareholders.

If you purchased or otherwise acquired Ocular securities between May 5, 2017 through July 6, 2017 (the "Class Period") and have questions about your legal rights or possess information relevant to this investigation, please contact attorney Bradley Vettraino at (617) 398-5600, by email at bradley@blockesq.com, or by visiting www.blockesq.com/ocular.  

The class action lawsuit alleges that throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (1) Ocular Therapeutix's management has been misleading investors about DEXTENZA manufacturing issues, including that more than 50% of lots manufactured by Ocular Therapeutix contain bad product; (2) such manufacturing issues could imperil the approval of DEXTENZA by the FDA; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times.

If you wish to serve as a lead plaintiff, you must move the Court no later than September 5, 2017.  As a member of the class, you may seek to file a motion to serve as a lead plaintiff or take no action and remain an absent class member. If you wish to become involved in the litigation or have questions about your legal rights, please contact attorney Bradley Vettraino at (617) 398-5600, by email at bradley@blockesq.com.

Confidentiality to whistleblowers or others with information relevant to this investigation is assured.